Linker Information
General Information of This Linker
| Linker ID |
LIN0VCLBF
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Mc-PEG2-Val-Cit-PABC
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C29H42N6O9
|
|||||
| Isosmiles |
CC(C)C(NC(=O)CCOCCOCCN1C(=O)C=CC1=O)C(=O)NC(CCCNC(N)=O)C(=O)Nc1ccc(CO)cc1
|
|||||
| InChI |
InChI=1S/C29H42N6O9/c1-19(2)26(34-23(37)11-14-43-16-17-44-15-13-35-24(38)9-10-25(35)39)28(41)33-22(4-3-12-31-29(30)42)27(40)32-21-7-5-20(18-36)6-8-21/h5-10,19,22,26,36H,3-4,11-18H2,1-2H3,(H,32,40)(H,33,41)(H,34,37)(H3,30,31,42)
|
|||||
| InChIKey |
NXGJAGHMGZCZSF-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
618.688
|
Polar area
|
218.49
|
||
|
Complexity
|
618.3013269
|
xlogp Value
|
-0.4602
|
|||
|
Heavy Count
|
44
|
Rot Bonds
|
20
|
|||
|
Hbond acc
|
9
|
Hbond Donor
|
6
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
BB-1701 [Phase 2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
50.00% (all)
70.60% (breast cancer) |
|||
| Patients Enrolled |
Patients with advanced/metastatic HER2-positive solid tumors, who had progressed on, or were intolerant to prior standard therapies, with ECOG PS 2, and measurable disease,.
|
||||
| Administration Dosage |
6 dose levels from 0.40 to 2.60 mg/kg Q3W.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04257110 | Clinical Status | Phase 1 | ||
| Clinical Description |
A first-in-human, open label, multiple dose, dose escalation and cohort expansion phase 1 study to investigate the safety, tolerability, pharmacokinetics and antitumor activities of bb-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors.
|
||||
BB-1705 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05217693 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
A phase 1/2 first-in-human, open label, multicenter, dose escalation and cohort expansion study to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BB-1705 in patients with locally advanced/metastatic solid tumors.
|
||||
References